Gliclazide API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

Produced in:

China

Established in: 2007

MOQ: -

Employees: 200+

GMP, WC, CEP, FDA, ISO Certificate

Arshine Group supplies more than 2,000 kinds of products

Arshine's marketing network has spread over more than 100 countries

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CEP

  • GMP

  • CoA

  • FDA

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

Produced in:

China

Established in: 2011

MOQ: 1 kg

Employees: 10+

Fast Response and Good Communication

Willingness To Start From Small

Flexible Payment Terms

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

  • BSE/TSE

  • MSDS

  • WC

  • ISO9001

  • GMP

Contact supplier

Replies within a day

Distributor

Produced in:

World

Established in: 2005

MOQ: -

Employees: 200+

Portfolio of over 2,000 APIs

Precise quality control

End-to-end global regulatory support

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CEP

  • GMP

  • CoA

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

Located in:

China

Passed ISO9001:2015 and SGS audit

Provide one-stop CDMO service from R&D to production

Certifications: ISO9001: 2015, HALAL Certificate, Kosher Certification

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • MSDS

  • CoA

  • ISO9001

Contact supplier

Replies quickly

Located in:

Italy

Producer

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

  • GMP

Contact supplier

Replies slower than most

Located in:

India
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

  • CEP

  • WC

  • GMP

  • FDA

Contact supplier

Replies slower than most

Located in:

India
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • WC

  • CoA

Contact supplier

Replies slower than most

Located in:

China
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

  • CEP

Contact supplier

Replies slower than most

Located in:

China
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • KDMF

  • coa

  • CEP

  • GMP

  • FDA

Contact supplier

Replies quickly

Located in:

India
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • GMP

  • CoA

Located in:

Italy

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Gliclazide API 21187-98-4?

Description:
Here you will find a list of producers, manufacturers and traders of Gliclazide. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Gliclazide 
Synonyms:
Gliclazida , Gliclazidum  
Cas Number:
21187-98-4 
DrugBank number:
DB01120 
Unique Ingredient Identifier:
G4PX8C4HKV

About Gliclazide

Want to know what Gliclazide is used for? Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.

Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).

Ask the supplier for a certificate of analysis to find out more about the quality of Gliclazide.

Gliclazide is a type of Sulfonylureas


Sulfonylureas belong to a subcategory of pharmaceutical active ingredients known as antidiabetic agents. These compounds play a crucial role in managing type 2 diabetes, a metabolic disorder characterized by high blood sugar levels. Sulfonylureas work by stimulating the pancreas to produce more insulin, a hormone responsible for regulating blood glucose levels.

As pharmaceutical API, sulfonylureas are highly effective in lowering blood sugar levels by promoting insulin secretion and increasing the sensitivity of cells to insulin. This mechanism of action makes them valuable in the treatment of type 2 diabetes, especially when other measures such as diet and exercise have proven inadequate.

Sulfonylureas are widely prescribed due to their proven efficacy, oral administration convenience, and cost-effectiveness. They are available in various formulations, including tablets and extended-release formulations, allowing flexibility in dosing regimens. Additionally, their long-established presence in the market has resulted in a comprehensive understanding of their safety profile and potential side effects.

Some common sulfonylurea drugs include glipizide, glimepiride, and gliclazide. These compounds are often prescribed as part of a comprehensive treatment plan for type 2 diabetes, along with lifestyle modifications and other antidiabetic medications.

It is important to note that the use of sulfonylureas should be carefully monitored by healthcare professionals to ensure optimal blood sugar control and to minimize the risk of hypoglycemia, a potential side effect. Patients taking sulfonylureas should also be educated about the importance of regular blood glucose monitoring and adhering to prescribed dosages.

In conclusion, sulfonylureas represent an essential subcategory of pharmaceutical APIs used in the treatment of type 2 diabetes. Their mechanism of action, proven efficacy, and cost-effectiveness make them a valuable tool in managing this chronic metabolic condition. Healthcare professionals play a vital role in guiding the appropriate use of sulfonylureas to optimize patient outcomes and ensure safety.


Gliclazide (Sulfonylureas), classified under Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.



Gliclazide manufacturers | traders | suppliers

We have 11 companies offering Gliclazide produced in 4 different countries.

Get in contact with the supplier of your choice:

  • Arshine Pharmaceutical Co., Limited from China, product country of origin China
  • Shandong Octagon Chemicals Limited from China, product country of origin China
  • LGM Pharma from United States, product country of origin World
  • Sinoway industrial Co.,Ltd from China, product country of origin China
  • Cosma from Italy, product country of origin Italy
  • Indoco Remedies from India, product country of origin India
  • Kreative Organics from India, product country of origin India
  • Shandong Fangming from China, product country of origin China
  • Shandong Keyuan from China, product country of origin China
  • Granules India from India, product country of origin India
  • Edmond Pharma (Recipharm) from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.